EGFR and neoplasm: Our results are in line with their observation that the effectiveness of trametinib depends on the complex and complete molecular background (mutation and expression); therefore, we supplemented our study with EGFR-pathway activity (protein phosphorylation) data, investigated the known feedback mechanism and offered possible therapeutic strategies for the different tumor subtypes.